Jatenzo Side Effects: Rare but Serious Adverse Events You Need to Know

Why Rare Side Effects of Jatenzo Deserve Serious Attention

Jatenzo was the first oral testosterone formulation approved in the United States since methyltestosterone, which was largely abandoned due to liver toxicity. Because Jatenzo uses a lymphatic absorption pathway rather than first-pass hepatic metabolism, its safety profile differs in meaningful ways from 17-alpha-alkylated predecessors. "oral" does not mean "risk-free." The FDA approval package for Jatenzo contains a boxed warning, a level of caution reserved for drugs with life-threatening potential harms. The full prescribing information is available at the FDA's accessdata portal.

Why the Lymphatic Route Changes (and Does Not Eliminate) Risk

Testosterone undecanoate is absorbed via intestinal lymphatics into the thoracic duct, bypassing hepatic first-pass metabolism. This sharply reduces the risk of peliosis hepatis and cholestatic jaundice that plagued methyltestosterone. However, the testosterone that eventually reaches systemic circulation is biologically identical to endogenous testosterone and to any other formulation. Cardiovascular, hematologic, and androgenic risks therefore persist.

The Key Phase 3 Trial in Brief

The JATENZO phase 3 program enrolled 166 hypogonadal men in a 90-day open-label study, followed by a 120-day extension. Serum testosterone levels were normalized in approximately 87% of subjects with twice-daily dosing titrated between 158 mg and 396 mg per day. Adverse event reporting from this trial forms the primary pharmacovigilance database for the drug, supplemented by post-marketing FAERS data. The FDA summary review for NDA 203098 is accessible on the agency's website.

Cardiovascular Adverse Events: The Boxed Warning Explained

The single most consequential safety signal for Jatenzo is blood pressure elevation, which appears prominently in the drug's boxed warning. In the phase 3 trials, mean systolic blood pressure increased by approximately 3.5 mmHg from baseline, and approximately 5% of participants required antihypertensive therapy initiation or intensification during the study. The prescribing information explicitly states that Jatenzo is contraindicated in men with uncontrolled hypertension.

Magnitude of Blood Pressure Elevation

A 3.5 mmHg average increase in systolic blood pressure may sound modest. Across a population, however, epidemiological data from the Prospective Studies Collaboration, analyzing over one million adults, showed that each 2 mmHg rise in systolic pressure is associated with a 7% higher risk of ischemic heart disease mortality and a 10% higher risk of stroke mortality. That analysis was published in The Lancet. The average masks individuals who experienced substantially larger increases, some exceeding 20 mmHg systolic during Jatenzo therapy.

Atherosclerosis, MACE, and the Testosterone Controversy

The broader question of whether testosterone replacement increases major adverse cardiovascular events (MACE) remains contested. The TRAVERSE trial (N=5,204), published in the New England Journal of Medicine in 2023, found that testosterone therapy was non-inferior to placebo for MACE over a median 33-month follow-up in men with hypogonadism and pre-existing or high-risk cardiovascular disease. TRAVERSE is available at NEJM. TRAVERSE used testosterone gel, not oral testosterone undecanoate, so direct extrapolation to Jatenzo requires caution. The blood pressure effect seen specifically with oral testosterone undecanoate was not replicated to the same degree with transdermal formulations in that trial.

Thromboembolic Events

All testosterone formulations carry a class-level warning for venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. The mechanism likely involves erythrocytosis-driven blood viscosity increases and direct effects on clotting factors. Post-marketing case reports submitted to the FDA's FAERS database document VTE events following Jatenzo initiation, consistent with the class label. The FDA drug safety communication on testosterone and VTE is available on the agency's safety page. Clinicians should document baseline thrombotic risk using a validated tool before prescribing.

Polycythemia and Hematologic Risks

Polycythemia, defined by hematocrit elevation above 54%, is one of the most consistently documented laboratory adverse events across all testosterone formulations. In the Jatenzo phase 3 trial, approximately 6% of subjects exceeded this threshold. The prescribing label details hematocrit monitoring requirements.

Mechanism of Erythrocytosis

Testosterone stimulates erythropoiesis through multiple pathways: direct stimulation of erythroid progenitor cells, suppression of hepcidin (which increases iron availability), and upregulation of renal erythropoietin production. The result is a dose-dependent increase in red cell mass. At hematocrit levels above 54%, blood viscosity rises enough to increase thrombotic risk meaningfully, which is why the Endocrine Society's 2018 clinical practice guideline recommends withholding testosterone therapy when hematocrit exceeds 54% until values normalize. The guideline is published in the Journal of Clinical Endocrinology and Metabolism.

Monitoring and Management

Baseline complete blood count should be obtained before starting Jatenzo. Repeat CBC at 3 months, then every 6 to 12 months. If hematocrit rises to 48 to 50%, reduce the Jatenzo dose. If it exceeds 54%, discontinue therapy until the value returns below 50%. Therapeutic phlebotomy is sometimes used in practice, though the Endocrine Society guideline notes it is not a substitute for dose reduction or discontinuation. The goal is to prevent the polycythemia-VTE cascade, not just to normalize the lab value.

Hepatic Effects: Better Than Methyltestosterone, Not Risk-Free

One of the main marketing distinctions for Jatenzo is its claimed hepatic safety advantage over 17-alpha-alkylated oral androgens. This is largely accurate. Peliosis hepatis, hepatic adenomas, and cholestatic jaundice were documented with methyltestosterone, and these have not been reported with testosterone undecanoate formulations at approved doses. A review in the journal Hepatology supports this mechanistic distinction.

What the Data Actually Show

Mild, transient elevations in ALT and AST have been reported in some Jatenzo trial participants, though rates were not statistically different from placebo arms in controlled studies. The FDA label does not require routine liver function testing specifically for Jatenzo the way older androgen labels did. However, clinicians should evaluate liver enzymes at baseline and consider monitoring in men with pre-existing hepatic disease, heavy alcohol use, or concurrent hepatotoxic medications.

Practical Guidance on Fatty Liver Risk

Hypogonadal men disproportionately carry visceral adiposity and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). Testosterone therapy may modestly improve hepatic steatosis by reducing visceral fat. A 12-month randomized trial published in the European Journal of Endocrinology (N=100) found that testosterone undecanoate injection reduced liver fat fraction compared to placebo in hypogonadal men with type 2 diabetes. That study is indexed on PubMed. The direction of effect for Jatenzo is likely similar, but head-to-head data against injectable testosterone undecanoate on liver fat endpoints do not yet exist.

Prostate Adverse Events

Testosterone therapy does not cause prostate cancer. That distinction matters. The historical moratorium on testosterone treatment in men with any prostate concerns was built on the "androgen hypothesis" articulated in the 1940s, which was never supported by prospective trial data. The Prostate Cancer Prevention Trial and subsequent cohort studies have not demonstrated a causal link between physiologic testosterone and incident prostate cancer. The Endocrine Society guideline addresses this directly.

PSA Elevation and Monitoring

PSA increases occur with Jatenzo, as with all testosterone formulations. In the phase 3 trial, mean PSA rose modestly from baseline, and a small number of men had PSA values that prompted urologic referral. The Endocrine Society recommends obtaining baseline PSA before testosterone initiation in men over 40 years of age, then repeating at 3 to 6 months, then annually. A confirmed PSA increase of more than 1.4 ng/mL above baseline within the first 12 months warrants urology evaluation.

Benign Prostatic Hyperplasia Exacerbation

Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia may worsen with testosterone therapy. Dihydrotestosterone (DHT), converted from testosterone via 5-alpha reductase in prostate tissue, drives prostatic stromal growth. Men with pre-existing LUTS scoring above 19 on the American Urological Association symptom index are generally considered poor candidates for testosterone therapy without urology co-management. Jatenzo's prescribing information lists worsening BPH as a risk requiring monitoring.

Sleep Apnea Exacerbation

Obstructive sleep apnea (OSA) affects an estimated 30 to 80% of men with obesity-related hypogonadism, the same population most likely to receive a testosterone prescription. Testosterone increases upper airway collapsibility and may blunt the hypercapnic ventilatory response, both of which worsen OSA severity. A randomized study published in JAMA Internal Medicine (N=67) demonstrated significant worsening of apnea-hypopnea index in testosterone-treated men with pre-existing OSA.

Screening Before Prescribing

Men reporting loud snoring, witnessed apneas, non-restorative sleep, or excessive daytime somnolence should be screened with the STOP-BANG questionnaire before Jatenzo is started. Polysomnography is warranted in high-risk individuals. Men already on CPAP therapy for OSA can generally receive testosterone therapy safely, provided their CPAP adherence is confirmed and sleep symptoms are re-evaluated 3 months after testosterone initiation.

A Practical Pre-Prescription Safety Framework

The following minimum safety screen applies before the first Jatenzo capsule is dispensed.

Absolute contraindications to rule out first:

• Systolic blood pressure persistently above 165 mmHg or diastolic above 100 mmHg
• Hematocrit above 50% at baseline
• Active or suspected prostate or breast cancer
• Severe untreated OSA (AHI above 30 without CPAP)
• Hypersensitivity to testosterone or sesame oil (Jatenzo capsules contain sesame oil as a vehicle)

Baseline labs required before dispensing:

• Serum total testosterone (morning, fasting)
• Complete blood count with hematocrit
• Comprehensive metabolic panel (including ALT, AST)
• PSA (age 40 and older, or any man with prostate risk factors)
• Blood pressure (two readings, seated, at rest)
• LH, FSH (to confirm hypogonadism type and guide monitoring)

Drug Interactions That Amplify Serious Risks

Jatenzo does not rely on CYP3A4 for absorption to the degree that older oral androgens did, but systemic testosterone is a CYP3A4 substrate once absorbed. Several drug interactions can amplify the serious adverse events described above.

Anticoagulants

Testosterone potentiates the anticoagulant effect of warfarin by inhibiting its metabolism. In men on warfarin, initiation of any testosterone formulation requires more frequent INR monitoring, typically at 1, 2, and 4 weeks after starting or dose-adjusting Jatenzo, then monthly until stable. A case series published in the Annals of Pharmacotherapy documented INR increases exceeding 3.5 in warfarin-maintained patients following testosterone initiation. That report is indexed on PubMed.

Insulin and Oral Hypoglycemics

Testosterone improves insulin sensitivity in hypogonadal men with type 2 diabetes. This is clinically desirable but creates hypoglycemia risk if antidiabetic regimens are not adjusted. The 12-month TIMES2 trial (N=220), published in the European Journal of Endocrinology, showed that intramuscular testosterone undecanoate significantly reduced HbA1c and fasting glucose in hypogonadal men with T2D. That trial is on PubMed. Men starting Jatenzo while on sulfonylureas or insulin should increase self-monitoring frequency for the first 90 days.

CYP3A4 Inhibitors and Inducers

Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) may raise testosterone exposure and amplify polycythemia and cardiovascular risk. Strong inducers (rifampin, carbamazepine) may reduce Jatenzo efficacy. Testosterone levels should be rechecked 4 to 6 weeks after any change to a patient's CYP3A4-interacting regimen.

Fertility, Axis Suppression, and Endocrine Adverse Events

Jatenzo suppresses the hypothalamic-pituitary-gonadal (HPG) axis. Exogenous testosterone feeds back negatively on GnRH, LH, and FSH secretion, reducing or eliminating endogenous testicular testosterone production and, critically, intratesticular testosterone needed for spermatogenesis. Azoospermia or severe oligospermia can develop within 3 months of testosterone therapy initiation in men with prior fertility potential. The American Urological Association guideline on male infertility addresses this directly.

Any man who has not completed his family or who has any desire for future biological paternity should be counseled explicitly before Jatenzo is started. Alternative treatments, including clomiphene citrate or anastrozole off-label, can raise endogenous testosterone without suppressing the HPG axis. Sperm cryopreservation is a reasonable option for men committed to testosterone therapy who want to preserve fertility.

Post-Marketing Surveillance: What FAERS Reveals

The FDA's Adverse Event Reporting System (FAERS) provides a continuous post-marketing signal for Jatenzo since its 2019 approval. Reports filed through 2024 capture real-world adverse events that extend beyond the controlled trial population, which excluded men with recent MACE, hematocrit above 50%, and several other high-risk features.

Most Frequently Reported Serious Events in FAERS

Post-marketing serious adverse event reports for Jatenzo include, in rough order of report frequency: hypertensive crisis, polycythemia vera-like erythrocytosis, pulmonary embolism, DVT, priapism, and hepatic enzyme elevation. Priapism, defined as a sustained unwanted erection exceeding 4 hours, is an androgenic adverse event requiring immediate urologic management to prevent permanent erectile dysfunction. Any erection lasting over 4 hours while on Jatenzo is a medical emergency.

Limitations of FAERS Data

FAERS is a passive, voluntary reporting system. It captures serious events that reach clinical attention, under-reporting mild-to-moderate events and capturing events from men who may have concurrent conditions contributing to the outcome. Causality cannot be established from FAERS data alone. These signals, however, prompted several label updates after initial approval and inform the boxed warning language in the current prescribing information.

Monitoring Schedule After Jatenzo Initiation

The Endocrine Society's 2018 testosterone therapy guideline recommends the following schedule, which applies to all testosterone formulations including Jatenzo. That guideline is published in JCEM.

The Endocrine Society guideline states: "We suggest monitoring testosterone levels, hematocrit, and PSA at 3 to 6 months after initiation of testosterone therapy and then annually thereafter."

At 3 months:

• Serum total testosterone (drawn 3 to 5 hours after the morning Jatenzo dose for Cmax approximation, or 8 to 10 hours after for Cavg approximation per FDA label guidance)
• Hematocrit
• Blood pressure
• Symptom response (International Index of Erectile Function, AUA-SI)

At 6 months:

• Repeat all 3-month labs
• PSA (men 40 and older)
• Fasting lipid panel (testosterone can modestly reduce HDL in some men)
• Liver enzymes in men with hepatic risk factors

Annually thereafter:

• All above
• Bone mineral density in men with osteoporosis indication
• Review of cardiovascular risk score (Framingham 10-year or ASCVD pooled cohort equation)

Special Populations With Amplified Risk

Men Over 65

The TRAVERSE trial enrolled men aged 45 to 80, with a mean age of 63. A pre-specified subgroup analysis found no significant age-by-treatment interaction for MACE, but men over 65 had numerically more atrial fibrillation events in the testosterone arm. Jatenzo's label notes that elderly men may be at higher risk for prostatic disease and cardiovascular events and recommends caution in this group.

Men With Chronic Kidney Disease

CKD stage 3 to 5 is associated with baseline erythropoietin dysregulation and anemia. Testosterone's erythropoietic effects can paradoxically worsen hematologic management in some CKD patients while helping in others. Hematocrit should be monitored monthly for the first 3 months in men with CKD stage 3 or above.

Men With Metabolic Syndrome or Type 2 Diabetes

This population derives measurable glycemic benefit from testosterone therapy but carries higher baseline cardiovascular risk. Initiation should follow shared decision-making using the ASCVD pooled cohort calculator, and a systolic blood pressure target below 130 mmHg should be established and maintained throughout treatment.